【摘要】：目的:探索TNF-α抑制劑對(duì)丙型肝炎病毒感染肝細(xì)胞的影響。方法:體外培養(yǎng)肝癌細(xì)胞株Huh7細(xì)胞,分為未處理組、NFκB抑制劑[6-amino-4-(4-phenoxyphenylethylamino)quinazoline,QNZ]處理組、咖啡酸苯乙酯(caffeic acid phenethyl ester,CAPE)處理組和TNF-α抑制劑來(lái)那度胺(Lenalidomide)處理組,每組設(shè)置濃度梯度為100μmol/L至1.28 nmol/L,5倍倍比稀釋,通過(guò)CCK8法檢測(cè)各抑制劑對(duì)細(xì)胞增殖的影響;Huh7細(xì)胞經(jīng)抑制劑處理后,再以丙型肝炎病毒感染,通過(guò)熒光定量PCR和免疫熒光法檢測(cè)細(xì)胞內(nèi)病毒的感染水平。結(jié)果:100μmol/L QNZ處理組(0.730±0.056)和100μmol/L CAPE處理組(1.040±0.014)細(xì)胞在450 nm處的吸光度(absorbance,A)值均低于未處理組(1.190±0.040,P=0.000)。Lenalidomide各濃度處理組(100μmol/L處理組,1.250±0.016)細(xì)胞增殖水平與未處理組相當(dāng)(P=0.306)。在抗病毒活性方面,100 nmol/L Lenalidomide處理組[(3.79±0.88)×105]和QNZ處理組[(6.64±1.11)×105]HCV RNA水平明顯低于未處理組[(1.51±0.45)×10~6,P=0.000],而CAPE處理組[(1.61±0.15)×10~6]與未處理組HCV RNA水平相當(dāng)(P=0.383)。結(jié)論:TNF-α抑制劑Lenalidomide對(duì)細(xì)胞毒性較小,能夠在細(xì)胞水平上抑制丙型肝炎病毒的感染。
[Abstract]:Objective: to explore the effect of TNF- 偽 inhibitor on hepatitis C virus (HCV) infected hepatocytes. Methods: hepatocellular carcinoma cell line Huh7 was cultured in vitro and divided into untreated group, NF 魏 B inhibitor [6-(4-phenoxyphenylethylamino) quinazoline,QNZ] group, caffeic acid phenethyl ester (caffeic acid phenethyl ester, group. CAPE) treatment group and TNF- 偽 inhibitor lenalidomide (Lenalidomide) treatment group, the concentration gradient of each group was 100 渭 mol / L to 1.28 nmol/L,5 times dilution, and the effect of each inhibitor on cell proliferation was detected by CCK8 method. Huh7 cells were treated with inhibitors and then infected with hepatitis C virus (HCV). The intracellular viral infection level was detected by fluorescence quantitative PCR and immunofluorescence assay. Results: the absorbance (absorbance,A) of the cells treated with 100 渭 mol / L QNZ (0.730 鹵0.056) and 100 渭 mol / L CAPE (1.040 鹵0.014) at 450 nm was lower than that of the untreated group (1.190 鹵0.040). The proliferation level of Lenalidomide treated group (100 渭 mol / L, 1.250 鹵0.016) was similar to that of non-treated group (P < 0. 306). In terms of antiviral activity, the level of HCV RNA in nmol/L Lenalidomide treatment group [(3.79 鹵0.88) 脳 10 ~ 5] and QNZ treatment group [(6.64 鹵1.11) 脳 10 ~ 5] was significantly lower than that in untreated group [(1.51 鹵0.45) 脳 10 脳 10 ~ 6, P < 0.001]. The level of HCV RNA in CAPE treated group [(1.61 鹵0.15) 脳 10 脳 10 6] was similar to that in untreated group (P = 0.383). Conclusion: Lenalidomide, an inhibitor of TNF- 偽, can inhibit hepatitis C virus infection at cell level.
【作者單位】： 成都軍區(qū)總醫(yī)院檢驗(yàn)科;成都軍區(qū)疾病預(yù)防控制中心;
【基金】：國(guó)家自然科學(xué)基金資助項(xiàng)目(編號(hào):81301445) 院管課題基金資助項(xiàng)目(編號(hào):2013YG-B055)
【分類(lèi)號(hào)】：R512.63
，

本文編號(hào)：2459205